Johnson & Johnson Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax
Johnson & Johnson (JNJ) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax of -$139.00 million for the 3-month period ending 2026-06-28, per its 10-Q filed 2026-07-23.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax · last filed 2026-07-23
- Johnson & Johnson other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for the quarter ending 2026-06-28 was -$139.00M, a 126.13% decline year-over-year.
- Johnson & Johnson other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for the quarter ending 2026-03-29 was -$77.00M, a 111.39% decline year-over-year.
- Johnson & Johnson other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for the quarter ending 2025-12-28 was $311.00M.
- Johnson & Johnson other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for the quarter ending 2025-09-28 was $434.00M, a 7.16% increase year-over-year.
- Johnson & Johnson other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2025 was $1.95B.
- Johnson & Johnson other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2024 was -$511.00M, a 221.09% decline from fiscal 2023.
- Johnson & Johnson other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2023 was $422.00M, a 7.05% decline from fiscal 2023.
- Johnson & Johnson other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2023 was $454.00M.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 3 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 3 month as first filed | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 6 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 6 month as first filed | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 9 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 12 month |
|---|---|---|---|---|---|---|
| 2026-06-28 | -$139.00M 10-Q · filed 2026-07-23 | -$216.00M 10-Q · filed 2026-07-23 | $95.00M derived: sum of 3 quarters · filed 2026-07-23 | $529.00M derived: sum of 4 quarters · filed 2026-07-23 | ||
| 2026-03-29 | -$77.00M 10-Q · filed 2026-04-22 | $234.00M derived: sum of 2 quarters · filed 2026-04-22 | $668.00M derived: sum of 3 quarters · filed 2026-04-22 | $1.20B derived: sum of 4 quarters · filed 2026-07-23 | ||
| 2025-12-28 | $311.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $745.00M derived: sum of 2 quarters · filed 2026-02-11 | $1.28B derived: sum of 3 quarters · filed 2026-07-23 | $1.95B 10-K · filed 2026-02-11 | ||
| 2025-09-28 | $434.00M 10-Q · filed 2025-10-22 | $966.00M derived: sum of 2 quarters · filed 2026-07-23 | $1.64B 10-Q · filed 2025-10-22 | $818.00M derived: sum of 4 quarters · filed 2026-07-23 | ||
| 2025-06-29 | $532.00M 10-Q · filed 2026-07-23 | $25.00M 10-Q · filed 2025-07-24 | $1.21B 10-Q · filed 2026-07-23 | -$117.00M 10-Q · filed 2025-07-24 | $384.00M derived: sum of 3 quarters · filed 2026-07-23 | $789.00M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-03-30 | $676.00M 10-Q · filed 2026-04-22 | -$142.00M 10-Q · filed 2025-04-23 | -$148.00M derived: sum of 2 quarters · filed 2026-04-22 | $257.00M derived: sum of 3 quarters · filed 2026-04-22 | $332.00M derived: sum of 4 quarters · filed 2026-04-22 | |
| 2024-12-29 | -$824.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$419.00M derived: sum of 2 quarters · filed 2026-02-11 | -$344.00M derived: sum of 3 quarters · filed 2026-02-11 | -$511.00M 10-K · filed 2026-02-11 | ||
| 2024-09-29 | $405.00M 10-Q · filed 2025-10-22 | $480.00M derived: sum of 2 quarters · filed 2025-10-22 | $313.00M 10-Q · filed 2025-10-22 | $815.00M derived: sum of 4 quarters · filed 2026-02-11 | ||
| 2024-06-30 | $75.00M 10-Q · filed 2025-07-24 | -$92.00M 10-Q · filed 2025-07-24 | $410.00M derived: sum of 3 quarters · filed 2026-02-11 | -$103.00M derived: sum of 4 quarters · filed 2026-02-11 | ||
| 2024-03-31 | -$167.00M 10-Q · filed 2025-04-23 | $335.00M derived: sum of 2 quarters · filed 2026-02-11 | -$178.00M derived: sum of 3 quarters · filed 2026-02-11 | -$315.00M derived: sum of 4 quarters · filed 2026-02-11 | ||
| 2023-12-31 | $502.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$11.00M derived: sum of 2 quarters · filed 2026-02-11 | -$148.00M derived: sum of 3 quarters · filed 2026-02-11 | $422.00M 10-K · filed 2026-02-11 | ||
| 2023-10-01 | -$513.00M 10-Q · filed 2024-10-23 | -$650.00M derived: sum of 2 quarters · filed 2024-10-23 | -$80.00M 10-Q · filed 2024-10-23 | $628.00M derived: sum of 4 quarters · filed 2025-02-13 | ||
| 2023-07-02 | -$137.00M 10-Q · filed 2024-07-25 | $433.00M 10-Q · filed 2024-07-25 | $1.14B derived: sum of 3 quarters · filed 2025-02-13 | $937.00M derived: sum of 4 quarters · filed 2025-02-13 | ||
| 2023-04-02 | $570.00M 10-Q · filed 2024-05-01 | $1.28B derived: sum of 2 quarters · filed 2025-02-13 | $1.07B derived: sum of 3 quarters · filed 2025-02-13 | $1.22B derived: sum of 4 quarters · filed 2025-02-13 | ||
| 2023-01-01 | $708.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $504.00M derived: sum of 2 quarters · filed 2025-02-13 | $649.00M derived: sum of 3 quarters · filed 2025-02-13 | $454.00M 10-K · filed 2025-02-13 | ||
| 2022-10-02 | -$204.00M 10-Q · filed 2023-10-27 | -$59.00M derived: sum of 2 quarters · filed 2023-10-27 | -$254.00M 10-Q · filed 2023-10-27 | -$398.00M derived: sum of 4 quarters · filed 2024-02-16 | ||
| 2022-07-03 | $145.00M 10-Q · filed 2023-07-31 | -$50.00M 10-Q · filed 2023-07-31 | -$194.00M derived: sum of 3 quarters · filed 2024-02-16 | -$127.00M derived: sum of 4 quarters · filed 2024-02-16 | ||
| 2022-04-03 | -$195.00M 10-Q · filed 2023-04-28 | -$339.00M derived: sum of 2 quarters · filed 2024-02-16 | -$272.00M derived: sum of 3 quarters · filed 2024-02-16 | $128.00M derived: sum of 4 quarters · filed 2024-02-16 | ||
| 2022-01-02 | -$144.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-16 | -$77.00M derived: sum of 2 quarters · filed 2024-02-16 | $323.00M derived: sum of 3 quarters · filed 2024-02-16 | -$199.00M 10-K · filed 2024-02-16 | ||
| 2021-10-03 | $67.00M 10-Q · filed 2022-10-27 | $467.00M derived: sum of 2 quarters · filed 2022-10-27 | -$55.00M 10-Q · filed 2022-10-27 | -$107.00M derived: sum of 4 quarters · filed 2023-02-16 | ||
| 2021-07-04 | $400.00M 10-Q · filed 2022-07-29 | -$122.00M 10-Q · filed 2022-07-29 | -$174.00M derived: sum of 3 quarters · filed 2023-02-16 | $25.00M derived: sum of 4 quarters · filed 2023-02-16 | ||
| 2021-04-04 | -$522.00M 10-Q · filed 2022-04-29 | -$574.00M derived: sum of 2 quarters · filed 2023-02-16 | -$375.00M derived: sum of 3 quarters · filed 2023-02-16 | -$354.00M derived: sum of 4 quarters · filed 2023-02-16 | ||
| 2021-01-03 | -$52.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $147.00M derived: sum of 2 quarters · filed 2023-02-16 | $168.00M derived: sum of 3 quarters · filed 2023-02-16 | $1.00B 10-K · filed 2023-02-16 | ||
| 2020-09-27 | $199.00M 10-Q · filed 2021-10-29 | $220.00M derived: sum of 2 quarters · filed 2021-10-29 | $1.05B 10-Q · filed 2021-10-29 | -$761.00M derived: sum of 4 quarters · filed 2022-02-17 | ||
| 2020-06-28 | $21.00M 10-Q · filed 2021-07-29 | $853.00M 10-Q · filed 2021-07-29 | -$960.00M derived: sum of 3 quarters · filed 2022-02-17 | $962.00M derived: sum of 4 quarters · filed 2022-02-17 | ||
| 2020-03-29 | $832.00M 10-Q · filed 2021-04-30 | -$981.00M derived: sum of 2 quarters · filed 2022-02-17 | $941.00M derived: sum of 3 quarters · filed 2022-02-17 | $1.03B derived: sum of 4 quarters · filed 2022-02-17 | ||
| 2019-12-29 | -$1.81B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $109.00M derived: sum of 2 quarters · filed 2022-02-17 | $195.00M derived: sum of 3 quarters · filed 2022-02-17 | -$107.00M 10-K · filed 2022-02-17 | ||
| 2019-09-29 | $1.92B 10-Q · filed 2020-10-23 | $2.01B derived: sum of 2 quarters · filed 2020-10-23 | $1.71B 10-Q · filed 2020-10-23 | |||
| 2019-06-30 | $86.00M 10-Q · filed 2020-07-24 | -$216.00M 10-Q · filed 2020-07-24 | ||||
| 2019-03-31 | -$302.00M 10-Q · filed 2020-04-29 | |||||
| 2018-09-30 | $262.00M 10-Q · filed 2019-10-28 | $201.00M derived: sum of 2 quarters · filed 2019-10-28 | $37.00M 10-Q · filed 2019-10-28 | |||
| 2018-07-01 | -$61.00M 10-Q · filed 2019-07-29 | -$225.00M 10-Q · filed 2019-07-29 | ||||
| 2018-04-01 | -$164.00M 10-Q · filed 2019-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |